HIF-2alpha PET Tracers for Tumor Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective means for imaging and monitoring hypoxia-inducible factor 2-alpha (HIF-2α) in cancerous and ischemic tissues, particularly for detecting HIF-2α-expressing tumors, monitoring resistance to HIF-2α inhibitors, and evaluating changes in HIF-2α expression over time in response to treatments.
Innovation Solution
Development of HIF-2α-specific radioactive tracers comprising an HIF-2α-specific inhibitor, such as PT2385, labeled with positron-emitting radioisotopes like 11C or 18F, for use in PET scans to detect HIF-2α-expressing tumors, monitor resistance, and assess changes in HIF-2α expression in response to therapies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional imaging methods are used, then general tissue imaging is possible, but specific detection of HIF-2α expression is not achievable
Solution Approach 1:
The patent uses HIF-2α-specific inhibitors (PT2385, PT2399) as intermediary molecules that selectively bind to HIF-2α protein. These inhibitors serve as mediators between the target (HIF-2α) and the detection system (PET scanner), enabling specific detection of HIF-2α expression through their radioactive labels without requiring direct imaging of the protein itself
Solution Approach 2:
The patent replaces conventional mechanical or chemical detection methods with nuclear medicine-based PET imaging. By substituting a radioactive label on the HIF-2α-specific inhibitor with a positron-emitting isotope, the system achieves high-precision molecular imaging through detection of positron annihilation photons, bypassing limitations of traditional imaging modalities
2Measurement precision
If invasive biopsy methods are used, then tissue sample analysis is possible, but patient comfort and treatment continuity are compromised
Solution Approach 1:
The patent replaces invasive mechanical biopsy procedures with non-invasive PET imaging. The radioactive tracer accumulates in HIF-2α-expressing tissues, and its distribution is visualized externally using a PET scanner, eliminating the need for tissue extraction while maintaining detection accuracy
Solution Approach 2:
The HIF-2α-specific radioactive tracer performs self-detection by selectively accumulating in target tissues based on its high affinity for HIF-2α. The tracer itself serves as both the targeting agent and the signaling source, eliminating the need for separate sampling and laboratory analysis steps
3Measurement precision
If static imaging is performed, then single-timepoint HIF-2α expression is detectable, but dynamic monitoring of treatment response is not possible
Solution Approach 1:
The patent enables continuous monitoring of HIF-2α expression by allowing repeated PET imaging studies at different time points during treatment. The radioactive tracer can be administered multiple times with appropriate dosing intervals, providing continuous data on treatment response and resistance development without interrupting the therapeutic process
Solution Approach 2:
The system transitions from static to dynamic monitoring by capturing temporal changes in HIF-2α expression. PET scans performed at baseline, during treatment, and after treatment completion reveal the dynamic evolution of HIF-2α levels, enabling assessment of treatment efficacy and detection of resistance mechanisms over time
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables non-invasive, precise detection and monitoring of HIF-2α expression in tumors and ischemic areas, facilitating targeted therapies and monitoring treatment efficacy and resistance development.
Implementation Method 1
The radioactive label is a positron emitting radioisotope
Implementation Method 2
The positron emitting radioisotope can be 11C or 18F
Implementation Method 3
subjecting the subject to a positron emission topography (PET) scan
Data Source
AI summary
Provided herein are hypoxia inducible factor 2-alpha (HIF-2α)-specific radioactive tracers, methods of use thereof, and methods of synthesis thereof. Specifically, provided herein are HIF-2α-specific radioactive tracers comprising an HIF-2α-specific agent developed as a therapeutic inhibitor and a positron emitting radioactive label. Embodiments provide methods of detecting an HIF-2α-expressing tumor, detecting an HIF-2α inhibitor resistant tumor, evaluating a change in HIF-2α expression in response to an anti-cancer treatment, detecting acquisition of HIF-2α inhibitor resistance, evaluating efficacy of an HIF-2α depletion therapy, or detecting or monitoring an ischemic area in a subject. Also provided are methods of synthesizing an HIF-2α-specific radioactive tracer.